Prevalence of Antimicrobial Resistance and Infectious Diseases in a Hospitalised Migrant Population in Paris, France, a Retrospective Study

Int J Public Health. 2022 Dec 15:67:1604792. doi: 10.3389/ijph.2022.1604792. eCollection 2022.

Abstract

Objectives: The aim of this study was to estimate the prevalence of anti-microbial resistance (AMR) carriage and its risk factors in hospitalized migrants. Additionally, the prevalence of infectious diseases was evaluated, as well as symptoms of psychological trauma. Methods: We conducted a retrospective monocentric cross-sectional study including all migrant patients recently arrived and hospitalised over a one-year period. Results: Among 101 patients, seventy-nine percent originated from Sub-Saharan Africa. The overall AMR carriage rate was 20.7% [95% CI: 12.4; 28.9%]. We isolated 5/92 methicillin-resistant Staphylococcus aureus strains (5.4%) and 15/92 extended-spectrum beta-lactamase-producing Enterobacteriaceae (16.4%). AMR carriage was associated with older age, region of origin and length of migration. Rates of HIV, HBV, and HCV infection were 39.6%, 32.7%, and 5%, reflecting sampling bias linked to reasons for hospitalization. Eleven percent had serological evidence of treponemasis and 7.8% had Chlamydia trachomatis infection. Symptoms of depression or post-traumatic stress disorder were observed for more than half the patients. Conclusion: It appears essential to offer a systematic and comprehensive post-arrival screening of AMR carriage, infectious diseases and psychological trauma to subjects who experienced migration.

Keywords: AMR carriage; ESBL-E; drepanocytosis; migrants; psychological disorders; schistosomiasis; sexual transmitted infections.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Communicable Diseases* / epidemiology
  • Cross-Sectional Studies
  • Drug Resistance, Bacterial
  • France
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Paris
  • Prevalence
  • Retrospective Studies
  • Transients and Migrants*

Substances

  • Anti-Bacterial Agents